HC Wainwright Issues Positive Estimate for SGMO Earnings

Key Points

• HC Wainwright has upgraded Sangamo Therapeutics' Q3 2025 earnings estimates to a projected $0.06 per share, a significant increase from their previous forecast of ($0.08).
• Despite the positive adjustment in forecast, overall sentiment is mixed with a consensus rating of "Hold" and an average target price of $4.50 on the stock.
• Sangamo Therapeutics reported a recent earnings miss with (0.08) EPS against an expected (0.07) EPS, and their last quarter revenue fell short at $18.31 million compared to a forecast of $31.68 million.

Sangamo Therapeutics, Inc. (NASDAQ:SGMO - Free Report) - Investment analysts at HC Wainwright increased their Q3 2025 earnings per share estimates for Sangamo Therapeutics in a report issued on Tuesday, August 12th. HC Wainwright analyst P. Trucchio now forecasts that the biopharmaceutical company will earn $0.06 per share for the quarter, up from their previous estimate of ($0.08). HC Wainwright currently has a "Buy" rating and a $10.00 target price on the stock. The consensus estimate for Sangamo Therapeutics' current full-year earnings is ($0.46) per share. HC Wainwright also issued estimates for Sangamo Therapeutics' FY2025 earnings at ($0.12) EPS, Q1 2026 earnings at ($0.05) EPS, Q2 2026 earnings at ($0.05) EPS, Q3 2026 earnings at ($0.06) EPS, FY2026 earnings at ($0.15) EPS, FY2027 earnings at ($0.02) EPS and FY2028 earnings at $0.15 EPS.

Sangamo Therapeutics (NASDAQ:SGMO - Get Free Report) last issued its quarterly earnings results on Thursday, August 7th. The biopharmaceutical company reported ($0.08) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.07) by ($0.01). Sangamo Therapeutics had a negative return on equity of 293.05% and a negative net margin of 77.48%.The company had revenue of $18.31 million for the quarter, compared to analyst estimates of $31.68 million.

Other analysts have also issued research reports about the stock. Barclays lowered their price target on shares of Sangamo Therapeutics from $9.00 to $5.00 and set an "overweight" rating for the company in a report on Wednesday, May 14th. Wall Street Zen upgraded Sangamo Therapeutics from a "sell" rating to a "hold" rating in a research report on Saturday. Four investment analysts have rated the stock with a Buy rating and two have issued a Hold rating to the company's stock. Based on data from MarketBeat.com, Sangamo Therapeutics presently has a consensus rating of "Moderate Buy" and a consensus price target of $4.50.

Sangamo Therapeutics Stock Performance

Shares of NASDAQ SGMO traded down $0.0125 during trading on Friday, reaching $0.5480. The company had a trading volume of 1,671,904 shares, compared to its average volume of 6,097,271. Sangamo Therapeutics has a 52 week low of $0.4111 and a 52 week high of $3.1790. The business's 50 day moving average price is $0.52 and its 200-day moving average price is $0.69. The stock has a market cap of $165.34 million, a PE ratio of -1.89 and a beta of 1.18.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently made changes to their positions in SGMO. Wasatch Advisors LP grew its stake in shares of Sangamo Therapeutics by 17.7% during the second quarter. Wasatch Advisors LP now owns 8,084,419 shares of the biopharmaceutical company's stock worth $4,376,000 after purchasing an additional 1,215,653 shares during the period. Engineers Gate Manager LP boosted its holdings in Sangamo Therapeutics by 101.7% during the second quarter. Engineers Gate Manager LP now owns 87,425 shares of the biopharmaceutical company's stock worth $47,000 after buying an additional 44,078 shares during the last quarter. Invesco Ltd. grew its position in shares of Sangamo Therapeutics by 40.6% during the 2nd quarter. Invesco Ltd. now owns 680,452 shares of the biopharmaceutical company's stock worth $368,000 after buying an additional 196,558 shares during the period. XTX Topco Ltd acquired a new position in shares of Sangamo Therapeutics during the 2nd quarter worth about $41,000. Finally, Geode Capital Management LLC increased its stake in shares of Sangamo Therapeutics by 2.1% in the 2nd quarter. Geode Capital Management LLC now owns 2,332,279 shares of the biopharmaceutical company's stock valued at $1,263,000 after acquiring an additional 48,829 shares during the last quarter. 56.93% of the stock is currently owned by institutional investors.

Sangamo Therapeutics Company Profile

Sangamo Therapeutics, Inc, a clinical-stage genomic medicine company, focuses on translating science into medicines that transform the lives of patients and families afflicted with serious diseases in the United States. The company's clinical-stage product candidates are ST-920, a gene therapy product candidate, which is in Phase 1/2 clinical study for the treatment of Fabry disease; TX200, a chimeric antigen receptor engineered regulatory T cell (CAR-Treg) therapy product candidate that is in Phase 1/2 clinical study for the prevention of immune-mediated rejection in HLA-A2 mismatched kidney transplantation; SB-525, a gene therapy product candidate, which is in Phase 3 clinical trial for the treatment of moderately severe to severe hemophilia A; BIVV003, a zinc finger nuclease gene-edited cell therapy product candidate that is in Phase 1/2 PRECIZN-1 clinical study for the treatment of sickle cell disease.